Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market

The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Comprehensive Study by End-User (Big Pharma, Small & Mid-size Pharma/Biotech Firms, Academic & Research Institutes, Others), Service Type (Drug Development, Manufacturing), Molecule Type (Small Molecules, Large Molecules (Biologics)), Therapeutic Area (Oncology, Cardiovascular, Infectious Diseases, Neurology, Others) Players and Region - Global Market Outlook to 2032

The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About The Pharmaceutical Contract Development and Manufacturing Organization (CDMO)
The Contract Development and Manufacturing Organization (CDMO) industry is a prime sector in the global biopharmaceutical and pharmaceutical industry. CDMOs are third-party outsourcing companies that provide end-to-end drug development and manufacturing solutions for pharmaceuticals on a contract basis. This ranges from early-stage development of drugs (preclinical research, formulation, and clinical trials) to commercial-scale manufacturing, packaging, and even post-launch activities. CDMOs allow pharma companies—particularly those without in-house expertise or wishing to drive down costs—to get new drugs to market more economically and efficiently. The main applications of CDMOs are lowering time-to-market, minimizing R&D and manufacturing expenses, obtaining specialized expertise and technology, and enhancing scalability and flexibility of operations. This model is especially effective for small and mid-sized biopharma companies, which lack the infrastructure to enable full drug lifecycle management. Moreover, even big pharma companies use CDMOs to handle product overflow or enter new markets with minimal capital expenditures. The CDMO industry is experiencing strong growth fueled by the increasing drug molecule complexity, rising outsourcing trends, expansion in biologics and biosimilars demand, and drug development time pressure from regulators. It also has a critical role in producing advanced therapies, such as cell and gene therapies and mRNA vaccines.

AttributesDetails
Study Period2020-2032
Base Year2024
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Lonza Group (Basel, Switzerland), Catalent Inc. ( Somerset, New Jersey, USA), Thermo Fisher Scientific (Patheon) (Waltham, Massachusetts, USA), WuXi AppTec ( Shanghai, China), Samsung Biologics (Incheon, South Korea), Recipharm AB (Stockholm, Sweden), Siegfried Holding AG ( Zofingen, Switzerland), Boehringer Ingelheim BioXcellence (Ingelheim am Rhein, Germany), Evonik Industries AG (Essen, Germany), Jubilant Pharmova (Noida, Uttar Pradesh, India), Cambrex Corporation (East Rutherford, New Jersey, USA), Piramal Pharma Solutions (Mumbai, Maharashtra, India), Curia (formerly AMRI) (Albany, New York, USA) and Alcami Corporation (Wilmington, North Carolina, USA) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market by and Region.



On the basis of geography, the market of The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by , the sub-segment i.e. will boost the The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Focus on End-to-End Services and Technological Advancements

Market Growth Drivers:
Rising Demand for Outsourcing and Growth of Biologics and Biosimilars

Challenges:
Maintaining Quality Standards Globally and Volatility in Supply Chains

Restraints:
Regulatory Complexity and IP and Confidentiality Concerns

Opportunities:
Surging Demand for mRNA and Gene Therapies and Digital Transformation

Market Leaders and their expansionary development strategies

In March 2025, Shilpa Medicare introduced a "Hybrid CDMO" model at DCAT Week 2025. This approach combines comprehensive discovery, clinical, and commercial outsourcing services with ready-to-license novel formulations, focusing on oncology, peptides, and biologics. and In January 2025, Akums Drugs & Pharmaceuticals initiated the development of a new facility dedicated to lyophilized and sterile dosage manufacturing, emphasizing injectables and biologics.

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By End-User
  • Big Pharma
  • Small & Mid-size Pharma/Biotech Firms
  • Academic & Research Institutes
  • Others

By Service Type
  • Drug Development
  • Manufacturing

By Molecule Type
  • Small Molecules
  • Large Molecules (Biologics)

By Therapeutic Area
  • Oncology
  • Cardiovascular
  • Infectious Diseases
  • Neurology
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Demand for Outsourcing
      • 3.2.2. Growth of Biologics and Biosimilars
    • 3.3. Market Challenges
      • 3.3.1. Maintaining Quality Standards Globally
      • 3.3.2. Volatility in Supply Chains
    • 3.4. Market Trends
      • 3.4.1. Increased Focus on End-to-End Services
      • 3.4.2. Technological Advancements
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User, Service Type, Molecule Type, Therapeutic Area and Region (value) (2019-2024)
    • 5.1. Introduction
    • 5.2. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) (Value)
      • 5.2.1. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: End-User (Value)
        • 5.2.1.1. Big Pharma
        • 5.2.1.2. Small & Mid-size Pharma/Biotech Firms
        • 5.2.1.3. Academic & Research Institutes
        • 5.2.1.4. Others
      • 5.2.2. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: Service Type (Value)
        • 5.2.2.1. Drug Development
        • 5.2.2.2. Manufacturing
      • 5.2.3. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: Molecule Type (Value)
        • 5.2.3.1. Small Molecules
        • 5.2.3.2. Large Molecules (Biologics)
      • 5.2.4. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: Therapeutic Area (Value)
        • 5.2.4.1. Oncology
        • 5.2.4.2. Cardiovascular
        • 5.2.4.3. Infectious Diseases
        • 5.2.4.4. Neurology
        • 5.2.4.5. Others
      • 5.2.5. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2024)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Lonza Group (Basel, Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Catalent Inc. ( Somerset, New Jersey, USA)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific (Patheon) (Waltham, Massachusetts, USA)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. WuXi AppTec ( Shanghai, China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Samsung Biologics (Incheon, South Korea)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Recipharm AB (Stockholm, Sweden)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Siegfried Holding AG ( Zofingen, Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Boehringer Ingelheim BioXcellence (Ingelheim am Rhein, Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Evonik Industries AG (Essen, Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Jubilant Pharmova (Noida, Uttar Pradesh, India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Cambrex Corporation (East Rutherford, New Jersey, USA)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Piramal Pharma Solutions (Mumbai, Maharashtra, India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Curia (formerly AMRI) (Albany, New York, USA)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Alcami Corporation (Wilmington, North Carolina, USA)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Sale, by End-User, Service Type, Molecule Type, Therapeutic Area and Region (value) (2027-2032)
    • 7.1. Introduction
    • 7.2. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) (Value)
      • 7.2.1. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: End-User (Value)
        • 7.2.1.1. Big Pharma
        • 7.2.1.2. Small & Mid-size Pharma/Biotech Firms
        • 7.2.1.3. Academic & Research Institutes
        • 7.2.1.4. Others
      • 7.2.2. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: Service Type (Value)
        • 7.2.2.1. Drug Development
        • 7.2.2.2. Manufacturing
      • 7.2.3. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: Molecule Type (Value)
        • 7.2.3.1. Small Molecules
        • 7.2.3.2. Large Molecules (Biologics)
      • 7.2.4. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: Therapeutic Area (Value)
        • 7.2.4.1. Oncology
        • 7.2.4.2. Cardiovascular
        • 7.2.4.3. Infectious Diseases
        • 7.2.4.4. Neurology
        • 7.2.4.5. Others
      • 7.2.5. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by End-User(USD Million)
  • Table 2. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Big Pharma , by Region USD Million (2019-2024)
  • Table 3. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Small & Mid-size Pharma/Biotech Firms , by Region USD Million (2019-2024)
  • Table 4. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Academic & Research Institutes , by Region USD Million (2019-2024)
  • Table 5. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Others , by Region USD Million (2019-2024)
  • Table 6. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by Service Type(USD Million)
  • Table 7. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Drug Development , by Region USD Million (2019-2024)
  • Table 8. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Manufacturing , by Region USD Million (2019-2024)
  • Table 9. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by Molecule Type(USD Million)
  • Table 10. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Small Molecules , by Region USD Million (2019-2024)
  • Table 11. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Large Molecules (Biologics) , by Region USD Million (2019-2024)
  • Table 12. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by Therapeutic Area(USD Million)
  • Table 13. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Oncology , by Region USD Million (2019-2024)
  • Table 14. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Cardiovascular , by Region USD Million (2019-2024)
  • Table 15. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Infectious Diseases , by Region USD Million (2019-2024)
  • Table 16. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Neurology , by Region USD Million (2019-2024)
  • Table 17. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Others , by Region USD Million (2019-2024)
  • Table 18. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2019-2024)
  • Table 19. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 20. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 21. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 22. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 23. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 24. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 25. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 26. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 27. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 28. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 29. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 30. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 31. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 32. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 33. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 34. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 35. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2019-2024)
  • Table 36. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 37. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 38. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 39. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 40. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 41. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 42. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 43. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 44. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 45. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 46. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 47. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 48. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 49. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 50. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 51. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 52. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 53. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 54. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 55. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 56. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 57. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 58. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 59. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 60. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 61. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 62. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 63. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 64. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 65. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 66. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 67. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 68. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2019-2024)
  • Table 69. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 70. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 71. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 72. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 73. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 74. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 75. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 76. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 77. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 78. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 79. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 80. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 81. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 82. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 83. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 84. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 85. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 86. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 87. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 88. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 89. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 90. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 91. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 92. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 93. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 94. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 95. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 96. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 97. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2019-2024)
  • Table 98. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 99. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 100. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 101. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 102. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 103. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 104. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 105. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 106. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 107. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 108. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 109. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 110. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2019-2024)
  • Table 111. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 112. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 113. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 114. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 115. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 116. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 117. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 118. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 119. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 120. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 121. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 122. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 123. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2019-2024)
  • Table 124. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2019-2024)
  • Table 125. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2019-2024)
  • Table 126. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2019-2024)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by End-User(USD Million)
  • Table 142. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Big Pharma , by Region USD Million (2027-2032)
  • Table 143. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Small & Mid-size Pharma/Biotech Firms , by Region USD Million (2027-2032)
  • Table 144. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Academic & Research Institutes , by Region USD Million (2027-2032)
  • Table 145. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Others , by Region USD Million (2027-2032)
  • Table 146. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by Service Type(USD Million)
  • Table 147. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Drug Development , by Region USD Million (2027-2032)
  • Table 148. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Manufacturing , by Region USD Million (2027-2032)
  • Table 149. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by Molecule Type(USD Million)
  • Table 150. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Small Molecules , by Region USD Million (2027-2032)
  • Table 151. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Large Molecules (Biologics) , by Region USD Million (2027-2032)
  • Table 152. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by Therapeutic Area(USD Million)
  • Table 153. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Oncology , by Region USD Million (2027-2032)
  • Table 154. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Cardiovascular , by Region USD Million (2027-2032)
  • Table 155. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Infectious Diseases , by Region USD Million (2027-2032)
  • Table 156. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Neurology , by Region USD Million (2027-2032)
  • Table 157. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Others , by Region USD Million (2027-2032)
  • Table 158. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2027-2032)
  • Table 159. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 160. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 161. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 162. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 163. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 164. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 165. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 166. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 167. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 168. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 169. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 170. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 171. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 172. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 173. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 174. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 175. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2027-2032)
  • Table 176. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 177. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 178. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 179. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 180. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 181. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 182. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 183. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 184. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 185. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 186. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 187. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 188. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 189. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 190. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 191. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 192. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 193. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 194. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 195. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 196. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 197. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 198. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 199. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 200. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 201. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 202. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 203. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 204. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 205. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 206. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 207. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 208. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2027-2032)
  • Table 209. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 210. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 211. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 212. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 213. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 214. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 215. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 216. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 217. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 218. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 219. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 220. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 221. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 222. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 223. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 224. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 225. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 226. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 227. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 228. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 229. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 230. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 231. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 232. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 233. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 234. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 235. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 236. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 237. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2027-2032)
  • Table 238. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 239. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 240. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 241. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 242. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 243. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 244. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 245. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 246. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 247. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 248. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 249. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 250. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2027-2032)
  • Table 251. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 252. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 253. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 254. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 255. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 256. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 257. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 258. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 259. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 260. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 261. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 262. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 263. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by End-User USD Million (2027-2032)
  • Table 264. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Service Type USD Million (2027-2032)
  • Table 265. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Molecule Type USD Million (2027-2032)
  • Table 266. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Therapeutic Area USD Million (2027-2032)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by End-User USD Million (2019-2024)
  • Figure 5. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by Service Type USD Million (2019-2024)
  • Figure 6. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by Molecule Type USD Million (2019-2024)
  • Figure 7. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by Therapeutic Area USD Million (2019-2024)
  • Figure 8. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 9. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 10. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 11. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 12. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 13. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) share by Players 2024 (%)
  • Figure 14. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) share by Players (Top 3) 2024(%)
  • Figure 15. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) share by Players (Top 5) 2024(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Lonza Group (Basel, Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Lonza Group (Basel, Switzerland) Revenue: by Geography 2024
  • Figure 19. Catalent Inc. ( Somerset, New Jersey, USA) Revenue, Net Income and Gross profit
  • Figure 20. Catalent Inc. ( Somerset, New Jersey, USA) Revenue: by Geography 2024
  • Figure 21. Thermo Fisher Scientific (Patheon) (Waltham, Massachusetts, USA) Revenue, Net Income and Gross profit
  • Figure 22. Thermo Fisher Scientific (Patheon) (Waltham, Massachusetts, USA) Revenue: by Geography 2024
  • Figure 23. WuXi AppTec ( Shanghai, China) Revenue, Net Income and Gross profit
  • Figure 24. WuXi AppTec ( Shanghai, China) Revenue: by Geography 2024
  • Figure 25. Samsung Biologics (Incheon, South Korea) Revenue, Net Income and Gross profit
  • Figure 26. Samsung Biologics (Incheon, South Korea) Revenue: by Geography 2024
  • Figure 27. Recipharm AB (Stockholm, Sweden) Revenue, Net Income and Gross profit
  • Figure 28. Recipharm AB (Stockholm, Sweden) Revenue: by Geography 2024
  • Figure 29. Siegfried Holding AG ( Zofingen, Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Siegfried Holding AG ( Zofingen, Switzerland) Revenue: by Geography 2024
  • Figure 31. Boehringer Ingelheim BioXcellence (Ingelheim am Rhein, Germany) Revenue, Net Income and Gross profit
  • Figure 32. Boehringer Ingelheim BioXcellence (Ingelheim am Rhein, Germany) Revenue: by Geography 2024
  • Figure 33. Evonik Industries AG (Essen, Germany) Revenue, Net Income and Gross profit
  • Figure 34. Evonik Industries AG (Essen, Germany) Revenue: by Geography 2024
  • Figure 35. Jubilant Pharmova (Noida, Uttar Pradesh, India) Revenue, Net Income and Gross profit
  • Figure 36. Jubilant Pharmova (Noida, Uttar Pradesh, India) Revenue: by Geography 2024
  • Figure 37. Cambrex Corporation (East Rutherford, New Jersey, USA) Revenue, Net Income and Gross profit
  • Figure 38. Cambrex Corporation (East Rutherford, New Jersey, USA) Revenue: by Geography 2024
  • Figure 39. Piramal Pharma Solutions (Mumbai, Maharashtra, India) Revenue, Net Income and Gross profit
  • Figure 40. Piramal Pharma Solutions (Mumbai, Maharashtra, India) Revenue: by Geography 2024
  • Figure 41. Curia (formerly AMRI) (Albany, New York, USA) Revenue, Net Income and Gross profit
  • Figure 42. Curia (formerly AMRI) (Albany, New York, USA) Revenue: by Geography 2024
  • Figure 43. Alcami Corporation (Wilmington, North Carolina, USA) Revenue, Net Income and Gross profit
  • Figure 44. Alcami Corporation (Wilmington, North Carolina, USA) Revenue: by Geography 2024
  • Figure 45. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by End-User USD Million (2027-2032)
  • Figure 46. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by Service Type USD Million (2027-2032)
  • Figure 47. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by Molecule Type USD Million (2027-2032)
  • Figure 48. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by Therapeutic Area USD Million (2027-2032)
  • Figure 49. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 50. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 51. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 52. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 53. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Lonza Group (Basel, Switzerland)
  • Catalent Inc. ( Somerset, New Jersey, USA)
  • Thermo Fisher Scientific (Patheon) (Waltham, Massachusetts, USA)
  • WuXi AppTec ( Shanghai, China)
  • Samsung Biologics (Incheon, South Korea)
  • Recipharm AB (Stockholm, Sweden)
  • Siegfried Holding AG ( Zofingen, Switzerland)
  • Boehringer Ingelheim BioXcellence (Ingelheim am Rhein, Germany)
  • Evonik Industries AG (Essen, Germany)
  • Jubilant Pharmova (Noida, Uttar Pradesh, India)
  • Cambrex Corporation (East Rutherford, New Jersey, USA)
  • Piramal Pharma Solutions (Mumbai, Maharashtra, India)
  • Curia (formerly AMRI) (Albany, New York, USA)
  • Alcami Corporation (Wilmington, North Carolina, USA)
Select User Access Type

Key Highlights of Report


Jul 2022 231 Pages 95 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Quantitative research analysis
Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Lonza Group (Basel, Switzerland), Catalent Inc. ( Somerset, New Jersey, USA), Thermo Fisher Scientific (Patheon) (Waltham, Massachusetts, USA), WuXi AppTec ( Shanghai, China), Samsung Biologics (Incheon, South Korea), Recipharm AB (Stockholm, Sweden), Siegfried Holding AG ( Zofingen, Switzerland), Boehringer Ingelheim BioXcellence (Ingelheim am Rhein, Germany), Evonik Industries AG (Essen, Germany), Jubilant Pharmova (Noida, Uttar Pradesh, India), Cambrex Corporation (East Rutherford, New Jersey, USA), Piramal Pharma Solutions (Mumbai, Maharashtra, India), Curia (formerly AMRI) (Albany, New York, USA) and Alcami Corporation (Wilmington, North Carolina, USA) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased Focus on End-to-End Services " is seen as one of major influencing trends for The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market during projected period 2024-2032.
The The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Report?

Have a Query? Click Here

Other Related Reports

Roll Compactor Comprehensive Study by Type (• <30Kg/Hour, • 30 – 200Kg/Hour, • >200Kg/Hour), Sales Channel (Online, Offline), End User (Pharmaceutical, Food and Beverage, Chemical, Others) Players an...
$ 3500
VLP Vaccines Comprehensive Study by Virus (Covid-19, Zika, HIV, Adeno-Associated Virus, Hepatitis C), Form (Tablet, Injectables, Capsules, Others), End Use (Hospitals, Specialty Clinics), Vaccine (Li...
$ 3650
Antithyroid Drug Comprehensive Study by Type (Propylthiouracil, Methimazole), Application (Hospital, Specialty Clinics), Distribution Channels (Hospital Dispensary, Retail Pharmacy, Online Pharmacy) ...
$ 3500
Yacon Syrup Comprehensive Study by Type (Conventional, Organic), Application (Household, Commercial), Packaging (Bottle, Can, Pouches, Others), Sales Channel (Online, Offline) Players and Region - Gl...
$ 3500
Nasal Antiseptics Comprehensive Study by Type (Lactoperoxidase, Lactoferrin, Interferons, Povidone- Iodine, Alcohols, Others), Application (Hospitals, Laboratories, Clinics, Others), Sales Channel (O...
$ 3500
Aflibercept Drug Comprehensive Study by Application (Diabetic Macular Edoema (DME), Age-Related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)), Distribution (Hospital Dispensary, ...
$ 3650